{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:11:23Z","timestamp":1786619483677,"version":"build-2736575974"},"reference-count":19,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2024.12712","type":"journal-article","created":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T06:54:13Z","timestamp":1726037653000},"source":"Crossref","is-referenced-by-count":5,"title":["Cytokine release syndrome and immune effector cell\u2011associated neurotoxicity syndrome in a melanoma patient treated with adjuvant pembrolizumab"],"prefix":"10.3892","volume":"28","author":[{"given":"Sebastian","family":"Ochenduszko","sequence":"first","affiliation":[{"name":"Department of Oncology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamberto","family":"Landete","sequence":"additional","affiliation":[{"name":"Department of Neurology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Martinez","sequence":"additional","affiliation":[{"name":"Department of Oncology, University Hospital of La Ribera, 46600 Alzira, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Feria","sequence":"additional","affiliation":[{"name":"Department of Hematology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Franc\u00e9s","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Torregrosa","sequence":"additional","affiliation":[{"name":"Department of Oncology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Maiques","sequence":"additional","affiliation":[{"name":"Department of Oncology, Doctor Peset University Hospital, 46017 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2024,9,11]]},"reference":[{"issue":"6716","key":"key20240927091424_b1-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22136716","article-title":"Neurological immunotoxicity from cancer treatment","volume":"22","author":"Wesley","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"557","key":"key20240927091424_b2-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release Syndrome: Analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharmacol"},{"issue":"e005841","key":"key20240927091424_b3-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005841","article-title":"Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: Case report and systematic review of the literature","volume":"11","author":"Liu","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2372875","key":"key20240927091424_b4-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2372875","article-title":"Cytokine release syndrome after treatment with immune checkpoint inhibitors: An observational cohort study of 2672 patients from Karolinska University Hospital in Sweden","volume":"13","author":"Hamida","year":"2024","journal-title":"Oncoimmunology"},{"issue":"807050","key":"key20240927091424_b5-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.807050","article-title":"Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: A case series of 25 patients and review of the literature","volume":"13","author":"Tay","year":"2022","journal-title":"Front Immunol"},{"issue":"e24380","key":"key20240927091424_b6-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e24380","article-title":"Severe cytokine release syndrome induced by immune checkpoint inhibitors in cancer patients-A case report and review of the literature","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"key":"key20240927091424_b7-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.2169\/internalmedicine.2429-23","article-title":"Severe cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome in a man receiving immune checkpoint inhibitors for lung cancer: A case report","volume":"63","author":"Tanaka","year":"2024","journal-title":"Intern Med"},{"key":"key20240927091424_b8-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"key20240927091424_b9-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28 (suppl_4)","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"95","key":"key20240927091424_b10-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"issue":"5190","key":"key20240927091424_b11-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10215190","article-title":"Cytokine release syndrome in the immunotherapy of hematological malignancies: The biology behind and possible clinical consequences","volume":"10","author":"Tvedt","year":"2021","journal-title":"J Clin Med"},{"key":"key20240927091424_b12-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2991\/chi.k.210117.001","article-title":"The many faces of cytokine release syndrome-related coagulopathy","volume":"3","author":"Wang","year":"2021","journal-title":"Clin Hematol Int"},{"key":"key20240927091424_b13-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"key20240927091424_b14-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis induced by immune checkpoint inhibitors: A systematic review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"},{"issue":"1973","key":"key20240927091424_b15-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: Insights into mechanisms and novel therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"40","key":"key20240927091424_b16-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-019-0580-3","article-title":"Chimeric antigen receptor T cell-related neurotoxicity: Mechanisms, clinical presentation, and approach to treatment","volume":"21","author":"Rice","year":"2019","journal-title":"Curr Treat Options Neurol"},{"key":"key20240927091424_b17-ETM-28-5-12712","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2147\/TCRM.S223468","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-Cell-induced cytokine release syndrome: Clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"e19741","key":"key20240927091424_b18-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019741","article-title":"A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors","volume":"99","author":"Ohira","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"306","key":"key20240927091424_b19-ETM-28-5-12712","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors","volume":"7","author":"Das","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T06:14:30Z","timestamp":1727417670000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2024.12712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,11]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,9,11]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2024.12712","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,11]]},"article-number":"423"}}